SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines -

SELLAS Life Sciences' GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2 The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date -

SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE: BMY) nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM). The trial included patients.

SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients

Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will present at the JMP Securities Life Sciences Conference to be held at the Lotte New York Palace in New York City on Wednesday, June 15, 2022, at 11:00 a.m. ET.

SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th

SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. The trial evaluated SELLAS' peptide immunotherapeutic combined with .

Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone -

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor -

SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML) Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML)

SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated -

SELLAS Life Sciences' Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022 SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022

SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor –

SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights

GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: SLS) across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan).  GFH009 is a highly selective small-molecule cyclin.

SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offering price of $5.40 per share and accompanying warrant. The warrants to purchase shares of common stock have an exercise price of $5.40 per share, are immediately exercisable and will expire five years from the date of issuance. All of the securities in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $25.0 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on April 5, 2022, subject to the satisfaction of customary closing conditions.

SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering

- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset -

SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor

Biopharmaceutical Veteran Brings More Than 25 Years of Experience to SELLAS Biopharmaceutical Veteran Brings More Than 25 Years of Experience to SELLAS

SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

3D189, also known as SELLAS' lead product candidate, galinpepimut-S (GPS), is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein, which is present and over-expressed in an array of hematological malignancies and solid tumors.

Sellas Life Sciences Shares Jump As China Approves Galinpepimut IND For Blood Cancer

Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response After Receiving Standard Treatment Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response After Receiving Standard Treatment

SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T. Burns has been promoted within the Company to Senior Vice President, Finance, and Chief Accounting Officer.

SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer

Claims in Derivative Suits Related to Activities of SELLAS' Predecessor, Galena Biopharma, Inc. Claims in Derivative Suits Related to Activities of SELLAS' Predecessor, Galena Biopharma, Inc.

SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.

SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:

SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on September 10, 2021 the United States District Court for the District of New Jersey (the "Court") issued an order (the "Preliminary Order") providing for preliminary approval of the proposed settlement of the claims relating to the Company's predecessor, Galena Biopharma, Inc., and asserted derivatively on behalf of the Company against the individual defendants named in the previously disclosed stockholder derivative actions (i) Keller v. Ashton, et al, Civil Action No. 2:17-cv-1777 (D.N.J.); and (ii) Johnson v. Schwartz, et al, Civil Action No. 2:18-cv-00903 (D.N.J.) pending before the Court in accordance with the Stipulation of Settlement, dated June 15, 2021 (the "Stipulation"). The Stipulation also resolves all claims asserted in another derivative action arising from the same facts, Jacobs v. Schwartz, et al, Case No. CIVMSC17-01222, (Calif. Sup. Ct., Contra Costa). The Stipulation calls for the Company to adopt certain policies relating to the potential future commercialization of the Company's clinical candidates and for the Company's insurer to pay plaintiff's counsel up to $270,000 in attorney's fees and reimbursement of expenses.  The Preliminary Order set a final settlement approval hearing for November 19, 2021.

News for SELLAS Life Sciences Group Stock (SLS)